Breast cancer vaccine - Anixa Biosciences/Cleveland Clinic
Alternative Names: Alpha-lactalbumin vaccine - Anixa Biosciences/Cleveland ClinicLatest Information Update: 29 Aug 2025
At a glance
- Originator Cleveland Clinic
- Developer Anixa Biosciences; Cleveland Clinic
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Triple negative breast cancer
Most Recent Events
- 20 Aug 2025 Anixa Biosciences receives patent allowance for breast cancer vaccine technology in China
- 04 Aug 2025 Anixa Biosciences announces commencement of US FDA approved IND transfer to support a phase II trial for Breast cancer
- 30 Jul 2025 Anixa Biosciences receives patent allowance for breast cancer vaccine technology in Canada